News, events, and resources
Mar 26, 2026
Opening: Senior Scientist or Associate Principal Scientist, LCMS Platforms
The Bioanalysis & Biomarkers Department specializes in Method Development, Method Validation, GLP/GCLP Bioanalysis for PK, ...
Mar 26, 2026
Opening: Senior Scientist or Associate Principal Scientist
The Bioanalysis & Biomarkers Department specializes in Method Development, Method Validation, GLP/GCLP Bioanalysis for PK, ...
Mar 26, 2026
Opening: Manager / Director of Quality Assurance
The Director of Quality Assurance will be responsible for the development, management, and continuous improvement of quality systems ...
Mar 23, 2026
Antibody Glycosylation: FDA requirements and Characterization
Fc glycosylation controls antibody efficacy and safety. Learn what FDA expects for characterization, manufacturing and biosimilar ...
Feb 16, 2026
San Diego Biotech Networking Event 2026: CMC and Development Discussions
Join Crystal Biosolutions in San Diego for an informal biotech networking evening focused on CMC, bioanalysis, and development strategy.
Feb 16, 2026
What Does the FDA Require to Approve a Monoclonal Antibody Biosimilar in 2026?
What does the FDA require to approve a monoclonal antibody biosimilar in 2026? Analytical, PK, clinical, and immunogenicity evidence ...
Feb 4, 2026
The 6 Most Common Analytical Gaps in Biosimilar Programs (and how to fix them)
Learn the six most common analytical gaps in biosimilar development, why regulators flag them, and how to fix them early to reduce ...
Feb 3, 2026
WCBP 2026: Why Comparability is a Challenge for Late-Stage Biopharma
WCBP 2026 highlights why comparability is now the key late-stage challenge, from analytical CQA assessment to regulatory expectations and ...
Jan 12, 2026
New Head of West Coast business development at CBS, Allan Cortes!
Allan Cortes joins CBS as Head of West Coast business development, bringing unparalleled experience in biotech and CRO business development.
Dec 22, 2025
Meet Us at WCBP 2026: All Symposium Details Included
Crystal Bio Solution is attending as exhibitor at WCBP 2026. What is WCBP, who should attend, and why it matters for CMC and biologics.
Opening: Senior Scientist or Associate Principal Scientist, LCMS Platforms
The Bioanalysis & Biomarkers Department specializes in Method Development, Method Validation, GLP/GCLP Bioanalysis for PK, ...
Opening: Senior Scientist or Associate Principal Scientist
The Bioanalysis & Biomarkers Department specializes in Method Development, Method Validation, GLP/GCLP Bioanalysis for PK, ...
Opening: Manager / Director of Quality Assurance
The Director of Quality Assurance will be responsible for the development, management, and continuous improvement of quality systems ...
San Diego Biotech Networking Event 2026: CMC and Development Discussions
Join Crystal Biosolutions in San Diego for an informal biotech networking evening focused on CMC, bioanalysis, and development strategy.
WCBP 2026: Why Comparability is a Challenge for Late-Stage Biopharma
WCBP 2026 highlights why comparability is now the key late-stage challenge, from analytical CQA assessment to regulatory expectations and ...
New Head of West Coast business development at CBS, Allan Cortes!
Allan Cortes joins CBS as Head of West Coast business development, bringing unparalleled experience in biotech and CRO business development.
Meet Us at WCBP 2026: All Symposium Details Included
Crystal Bio Solution is attending as exhibitor at WCBP 2026. What is WCBP, who should attend, and why it matters for CMC and biologics.
Opening: Senior Scientist or Associate Principal Scientist, LCMS Platforms
The Bioanalysis & Biomarkers Department specializes in Method Development, Method Validation, GLP/GCLP Bioanalysis for PK, ...
Opening: Senior Scientist or Associate Principal Scientist
The Bioanalysis & Biomarkers Department specializes in Method Development, Method Validation, GLP/GCLP Bioanalysis for PK, ...
Opening: Manager / Director of Quality Assurance
The Director of Quality Assurance will be responsible for the development, management, and continuous improvement of quality systems ...
Antibody Glycosylation: FDA requirements and Characterization
Fc glycosylation controls antibody efficacy and safety. Learn what FDA expects for characterization, manufacturing and biosimilar ...
What Does the FDA Require to Approve a Monoclonal Antibody Biosimilar in 2026?
What does the FDA require to approve a monoclonal antibody biosimilar in 2026? Analytical, PK, clinical, and immunogenicity evidence ...
The 6 Most Common Analytical Gaps in Biosimilar Programs (and how to fix them)
Learn the six most common analytical gaps in biosimilar development, why regulators flag them, and how to fix them early to reduce ...
